Sage Journals: Discover world-class research

Abstract

ProSavin^® is a lentiviral vector (LV)-based gene therapy for Parkinson's disease. ProSavin^® is currently in a Phase I/II clinical trial using material that was generated by transient transfection of adherent human embryonic kidney (HEK)293T cells. For future large-scale productions of ProSavin^®, we have previously reported the development and characterization of two inducible producer cell lines, termed PS5.8 and PS46.2. PS46.2 has been successfully adapted to grow in suspension cultures. The present study describes the creation of a small-scale (<2 ml) microwell-based experimental platform for the parallel investigation of ProSavin^® production using suspension-adapted PS46.2. This is combined with statistical design of experiments (DoE) techniques to enable rapid characterization of the process conditions that impact cell growth and LV production. The effects of postinduction period, microwell liquid fill volume, and concentration of inducer (doxycycline) on ProSavin^® titer and the particle:infectivity (P:I) ratio was investigated using three rounds of DoE, in order to identify appropriate factor ranges and optimize production conditions. We identified an optimal “harvest window” between approximately 26–46 hr within which maximal titers of around 6×10⁴ transducing units (TU)/ml were obtained (an approximately 30-fold improvement compared to starting microwell conditions), providing that the fill volume was maintained at or below 1 ml and the doxycycline concentration was at least 1.0 μg/ml. Insights from the microwell studies were subsequently used to rapidly establish operating conditions for ProSavin^® production in a 0.5-L wave bioreactor culture. The information presented herein thus aids the design and evaluation of scalable production processes for LVs.

Guy and colleagues design a microwell-based experimental platform for evaluating production of a lentiviral-based gene therapy (ProSavin®) for Parkinson's disease using a previously characterized suspension-adapted inducible producer cell line. Processing conditions that impact cell growth and lentiviral production were also determined and used to rapidly establish operating conditions for ProSavin® production in a 0.5-L wave bioreactor culture.

Get full access to this article

View all access options for this article.

References

Anderson

M.J.

, Whitcomb

P.J.

2007. DOE Simplified: Practical Tools for Effective Experimentation. Productivity Press: New York.

Andreadis

, Lavery

, Davis

H.E.

et al. 2000. Toward a more accurate quantitation of the activity of recombinant retroviruses: alternatives to titer and multiplicity of infection. J. Virol., 74:1258–1266.

Ansorge

, Lanthier

, Transfiguracion

et al. 2009. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures. J. Gene Med., 11:868–876.

Ansorge

, Henry

, Kamen

2010. Recent progress in lentiviral vector mass production. Biochem. Eng. J., 48:362–377.

Ansorge

, Lanthier

, Transfiguracion

et al. 2011. Monitoring lentiviral vector production kinetics using online permittivity measurements. Biochem. Eng. J., 54:16–25.

Azzouz

, Martin-Rendon

, Barber

R.D.

et al. 2002. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J. Neurosci., 22:10302–10312.

Barrett

T.A.

, Wu

, Zhang

et al. 2010. Microwell engineering characterization for mammalian cell culture process development. Biotechnol. Bioeng., 105:260–275.

Broussau

, Jabbour

, Lachapelle

et al. 2008. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol. Ther., 16:500–507.

Büchs

, Maier

, Milbradt

, Zoels

2000. Power consumption in shaking flasks on rotary shaking machines: II. Nondimensional description of specific power consumption and flow regimes in unbaffled flasks at elevated liquid viscosity. Biotechnol. Bioeng., 68:594–601.

10.

Büchs

, Lotter

, Milbradt

2001. Out-of-phase operating conditions, a hitherto unknown phenomenon in shaking bioreactors. Biochem. Eng. J., 7:135–141.

11.

Burns

J.C.

, Friedmann

, Driever

et al. 1993. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U.S.A., 90:8033–8037.

12.

Carmo

, Alves

, Rodrigues

A.F.

et al. 2009a. Stabilization of gammaretroviral and lentiviral vectors: from production to gene transfer. J. Gene Med., 11:670–678.

13.

Carmo

, Dias

J.D.

, Panet

et al. 2009b. Thermosensitivity of the reverse transcription process as an inactivation mechanism of lentiviral vectors. Hum. Gene Ther., 20:1168–1176.

14.

Chen

, Liu

, Xie

et al. 2001. Engineering of a mammalian cell line for reduction of lactate formation and high monoclonal antibody production. Biotechnol. Bioeng., 72:55–61.

15.

Cockrell

A.S.

, Ma

, Fu

et al. 2006. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol. Ther., 14:276–284.

16.

Davis

H.E.

, Morgan

J.R.

, Yarmush

M.L.

2002. Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes. Biophys. Chem., 97:159–172.

17.

Doig

S.D.

, Pickering

S.C.R.

, Lye

G.J.

, Baganz

2005. Modelling surface aeration rates in shaken microtiter plates using dimensionless groups. Chemical Engineering Science, 60:2741–2750.

18.

Doran

P.M.

1995. Bioprocess Engineering Principles. Academic Press: London.

19.

Duetz

W.A.

, Ruedi

, Hermann

et al. 2000. Methods for intense aeration, growth, storage, and replication of bacterial strains in microtiter plates. Appl. Environ. Microbiol., 66:2641–2646.

20.

Eriksson

, Johansson

, Kettaneh-Wold

et al. 2008. Design of Experiments: Principles and Applications. MKS Umetrics AB: Umeå.

21.

Ferreira-Torres

, Micheletti

, Lye

G.J.

2005. Microscale process evaluation of recombinant biocatalyst libraries: application to Baeyer-Villiger monooxygenase catalysed lactone synthesis. Bioprocess Biosyst. Eng., 28:83–93.

22.

Genzel

, Olmer

R.M.

, Schafer

, Reichl

2006. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine, 24:6074–6087.

23.

Happel

J.R.

, Brenner

1983. Low Reynolds Number Hydrodynamics with Special Applications to Particulate Matter. Martinus Nijhoff Publishers: The Hague.

24.

Higashikawa

, Chang

2001. Kinetic analyses of stability of simple and complex retroviral vectors. Virology, 280:124–131.

25.

Islam

R.S.

, Tisi

, Levy

M.S.

, Lye

G.J.

2007. Framework for the rapid optimization of soluble protein expression in Escherichia coli combining microscale experiments and statistical experimental design. Biotechnol. Prog., 23:785–793.

26.

Islam

R.S.

, Tisi

, Levy

M.S.

, Lye

G.J.

2008. Scale-up of Escherichia coli growth and recombinant protein expression conditions from microwell to laboratory and pilot scale based on matched kLa. Biotechnol. Bioeng., 99:1128–1139.

27.

Jarraya

, Boulet

, Ralph

G.S.

et al. 2009. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci. Transl. Med., 1:2ra4.

28.

Klages

, Zufferey

, Trono

2000. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol. Ther., 2:170–176.

29.

Liu

, Liu

X.M.

, Wu

B.C.

et al. 2006. Effects of hydrodynamics on aggregates formation, growth and metabolism of HEK293 cells in suspension culture. Chin. J. Biotech., 22:101–106.

30.

Lotter

, Büchs

2004. Utilization of specific power input measurements for optimization of culture conditions in shaking flasks. Biochem. Eng. J., 17:195–203.

31.

Merten

O.W.

, Cruz

P.E.

, Rochette

et al. 2001. Comparison of different bioreactor systems for the production of high titer retroviral vectors. Biotechnol. Prog., 17:326–335.

32.

Micheletti

, Barrett

, Doig

et al. 2006. Fluid mixing in shaken bioreactors: Implications for scale-up predictions from microlitre-scale microbial and mammalian cell cultures. Chem. Eng. Sci., 61:2939–2949.

33.

Mitrophanous

, Yoon

, Rohll

et al. 1999. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther., 6:1808–1818.

34.

Naldini

1998. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr. Opin. Biotechnol., 9:457–463.

35.

Naldini

, Blomer

, Gallay

et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 272:263–267.

36.

Nanou

, Azzouz

2009. Gene therapy for neurodegenerative diseases based on lentiviral vectors. Prog. Brain Res., 175:187–200.

37.

Schweizer

, Merten

O.W.

2010. Large-scale production means for the manufacturing of lentiviral vectors. Curr. Gene Ther., 10:474–486.

38.

Segura

M.M.

, Kamen

, Garnier

2006. Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol. Adv., 24:321–337.

39.

Segura

M.M.

, Garnier

, Durocher

et al. 2007. Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnol. Bioeng., 98:789–799.

40.

Silk

N.J.

, Denby

, Lewis

et al. 2010. Fed-batch operation of an industrial cell culture process in shaken microwells. Biotechnol. Lett., 32:73–78.

41.

Singh

1999. Disposable bioreactor for cell culture using wave-induced agitation. Cytotechnology, 30:149–158.

42.

Stewart

H.J.

, Leroux-Carlucci

M.A.

, Sion

C.J.

et al. 2009. Development of inducible EIAV-based lentiviral vector packaging and producer cell lines. Gene Ther., 16:805–814.

43.

Stewart

H.J.

, Fong-Wong

, Strickland

et al. 2011. A stable producer cell line for the manufacture of a lentiviral vector for gene therapy of Parkinson's disease. Hum. Gene Ther., 22:357–369.

44.

Throm

R.E.

, Ouma

A.A.

, Zhou

et al. 2009. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood, 113:5104–5110.

45.

Wernli

, Eibl

2008. CD 293 AGT^™ medium for the cultivation of HEK 293 EBNA cells in small-scale bioreactors: an application report. In Quest, 5,1:18–21.

46.

Witting

S.R.

, Li

L.H.

, Jasti

et al. 2012. Efficient large volume lentiviral vector production using flow electroporation. Hum. Gene Ther., 23:243–249.

47.

, Ma

, McCown

T.J.

et al. 2001. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol. Ther., 3:97–104.

48.

Yee

J.K.

, Miyanohara

, Laporte

et al. 1994. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. U.S.A., 91:9564–9568.

49.

Zhang

, Metharom

, Jullie

et al. 2004. The significance of controlled conditions in lentiviral vector titration and in the use of multiplicity of infection (MOI) for predicting gene transfer events. Genet. Vaccines Ther., 2:6.

Characterization of Lentiviral Vector Production Using Microwell Suspension Cultures of HEK293T-Derived Producer Cells

Abstract

Get full access to this article

References